A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of asp0113, a dna-based cmv vaccine, in seropositive allogeneic haematopoietic cell transplant recipients

HIGHLIGHTS

• who: Per Ljungman from the Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital and Division of Hematology, Department of Medicine Marques de Valdecilla, Santander, Spain have published the paper: A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients, in the Journal: (JOURNAL) of 30/06/2020
• what: The development of an effective CMV vaccine was viewed as a promising therapeutic option to prevent CMV EOD, but the failure of this study has underlined . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.